Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | IBI310 |
| Trade Name | |
| Synonyms | IBI-310|IBI 310 |
| Drug Descriptions |
IBI310 is an antibody targeting CTLA4 (CD152), which potentially induces antitumor activity (PMID: 38881798). |
| DrugClasses | CTLA4 Antibody 33 |
| CAS Registry Number | NA |
| NCIT ID | C175970 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| IBI310 | IBI310 | 0 | 0 |
| IBI310 + SHR-1316 | IBI310 SHR-1316 | 0 | 0 |
| IBI310 + Sintilimab | IBI310 Sintilimab | 0 | 0 |